Chronic Rhinosinusitis: Adult Care and Adjunct Evidence

by

Direct answer

Adult chronic rhinosinusitis needs compatible symptoms for at least 12 weeks plus objective evidence of inflammation. Current guidance supports saline irrigation, topical nasal corticosteroids, or both. Selected persistent nasal-polyp disease may warrant specialist surgery or biologic discussion; a newer sponsored trial favored dupilumab over omalizumab in severe polyps plus asthma. Vitamin D, xylitol, probiotics and topical NAC have limited, population-specific findings; bromelain has not demonstrated clinical efficacy in the cited placebo trial. Use safe rinse water and follow clinician/product instructions.

Key takeaways
  • This article concerns adult chronic rhinosinusitis (CRS), which lasts at least 12 weeks and requires compatible symptoms plus objective evidence of sinonasal inflammation. Diagnosis and treatment differ from a short-lived viral illness or allergic rhinitis (2025 adult guideline).
  • The adult guideline recommends saline nasal irrigation, topical intranasal corticosteroids, or both, for symptom relief. The older two-trial saline review has low/very-low-certainty findings; that limited trial set should not be confused with the broader guideline recommendation (Current guidance; Original Cochrane review; Public summary).
  • Biologics are specialist options for selected persistent nasal-polyp CRS, not routine treatment for CRS without polyps. An older three-drug indirect ranking is not an all-option comparison. A newer head-to-head trial favored dupilumab over omalizumab for polyp and smell endpoints in adults who also had asthma, with commercial sponsorship disclosed (Adult guidance; Historical abstract; EVEREST).
  • The 2011 postoperative pilot analyzed 15 of 20 participants, with a small SNOT-20 difference below its stated clinical-importance threshold and no VAS benefit. The 2024 postoperative trial randomized 70 people one month after surgery and found no significant between-group superiority over saline after eight weeks. Grade: Weak (2011 pilot; 2024 original).
  • The 2018 tissue study detected bromelain immunoreactivity after dosing, without testing symptom relief. A separate Ursapharm-sponsored 40-person placebo trial did not demonstrate benefit on its primary symptom/rescue-medication score or SNOT-20; peak nasal inspiratory flow favored placebo. Grade: Insufficient for routine clinical use (Tissue study; Registered results; Original synopsis).
  • Vitamin D supplementation has limited postoperative evidence in low-vitamin-D nasal-polyp populations. The small trial’s findings do not establish routine supplementation for all CRS, and the review and trial contain reporting inconsistencies. Grade: Weak (Review; Original trial).
  • Probiotic results are mixed and do not establish routine CRS treatment. A small topical NAC postoperative trial found no benefit on overall symptom questionnaires or endoscopy, despite brief individual-symptom signals. No quercetin or curcumin CRS original was evaluated here; this is a review limit, not proof that no study exists (Probiotic review; NAC trial).

Adult CRS care starts with confirming the diagnosis and assessing polyps and modifying conditions. Current guidance supports saline, topical nasal corticosteroids, or both; persistent polyp disease may warrant specialist discussion of surgery and biologics. The adjunct studies below are limited, heterogeneous or poorly reported and should not replace prescribed care. Reported sponsorship, author relationships and original-paper access are disclosed separately (2025 adult guideline; Saline original review; Head-to-head trial; Vitamin D trial; Xylitol trial; Probiotic review; NAC trial; Bromelain synopsis).

Table of contents

Claim Evidence Source Reported funding / access limits Editorial grade
Saline irrigation for symptom relief The 2016 Cochrane review included two unblinded trials with 116 relevant participants. The positive large-volume study mixed recurrent acute and chronic diagnoses without objective CRS confirmation; its symptom/quality-of-life evidence was low or very low certainty. Broader adult guidance recommends saline, INCS, or both. Original Cochrane review; Summary; Adult guideline NIHR award 14/174/03 and Cochrane ENT infrastructure support; several review authors disclosed device/pharmaceutical relationships. Rabago reported a Wisconsin departmental small grant; Cassandro acknowledged IBSA-sponsored editorial assistance. Trial conflict declarations and complete financing/supply terms remain incomplete. Weak for the two trials; guideline-supported care
Topical intranasal corticosteroids Adult guidance recommends saline, INCS, or both. Mawkili combines biologic add-ons, delivery-device and pediatric studies; it is not six isolated steroid-monotherapy trials. Adult guideline; 2025 review Guideline funded by AAO-HNSF with commercial author relationships disclosed. Mawkili authors declared no submitted-work support or relevant relationships; included-trial finance remains separate. Strong for guideline support; review effects qualified
Biologics in selected nasal-polyp CRS EVEREST randomized 360 adults with severe nasal-polyp CRS and coexisting asthma to dupilumab or omalizumab plus mometasone for 24 weeks. Dupilumab improved the two primary polyp and smell endpoints more. This Sanofi/Regeneron-sponsored trial does not rank every biologic or establish the same result in CRS without polyps or asthma. Wu’s 2022 abstract reports an older three-agent indirect ranking. EVEREST original record; Historical NMA abstract; Contextual review Sanofi and Regeneron funded and participated in design, analysis, interpretation, writing and submission approval. Employee authors may hold stock/options; other commercial relationships and sponsor-funded medical writing were disclosed. Wu full methods/funding/COI unavailable. Moderate; specific comparator and population
Xylitol irrigation The 2011 postoperative pilot analyzed 15 of 20 participants, with a small SNOT-20 difference below its stated clinical-importance threshold and no VAS benefit. The 2024 postoperative trial randomized 70 people one month after surgery and found no significant between-group superiority over saline after eight weeks 2011 pilot; 2024 trial 2011: internal Stanford departmental support, no other funding/financial ties/COI disclosed. 2024: Taichung Veterans General Hospital grants TCVGH-1097326D/1107308D, no COI declared; underlying donors and purchase/donation terms not reported. Weak
Vitamin D as an adjunct The 2024 review is mostly observational and reports trial-count and classification inconsistencies. In the 2023 postoperative CRSwNP trial, 70 people with low vitamin D were randomized and 60 analyzed, all receiving saline and fluticasone. Symptoms and polyp recurrence favored supplementation at six months; attrition and contradictory treatment-duration wording limit interpretation. This does not establish a routine all-CRS regimen. Review; Original trial Review authors declared no competing interests; dedicated review cash support was not located. Ghazavi declared nil financial support and no conflicts; product procurement was not reported. Weak
Probiotics The four-trial review combined heterogeneous preparations and outcomes. Pooled SNOT scores were not significantly improved; a relapse signal came from selected individual studies rather than a universal effect. Reported routes and follow-up descriptions are inconsistent, so it does not establish an optimal product or regimen Fong 2023 review Review authors declared no competing interests and acknowledged hospital statistical advice. Dedicated cash support and included-trial financing/procurement were not reported in the recovered review. Weak; routine use unestablished
Bromelain The 2018 tissue study detected bromelain immunoreactivity after dosing, without testing symptom relief. A separate Ursapharm-sponsored 40-person placebo trial did not demonstrate benefit on its primary symptom/rescue-medication score or SNOT-20; peak nasal inspiratory flow favored placebo Passali 2018; Registered results; Full synopsis Tissue-study funding/COI and supply terms not reported in recovered paper; separate placebo trial sponsored by Ursapharm. Insufficient for routine efficacy
Topical N-acetylcysteine after surgery A small 2024 trial randomized 49 adults with CRS without polyps after sinus surgery; 47 were analyzed. Topical NAC plus saline did not outperform saline on SNOT-20, NOSE or endoscopic scores. Three individual symptoms favored NAC only at two weeks, with no difference at one or three months; patients were unblinded and multiple outcomes were tested Wee 2024 original Chungbuk National University 2022 grant 2022101232; authors declared no COI and no funder role. Product purchase/donation terms were not reported. Weak; routine use unestablished
Essential oils No essential-oil CRS original was evaluated here. Findings for acute sinusitis or perceived airflow cannot be assigned to chronic disease. No primary CRS trial assessed here Financial provenance not assessed Insufficient
Quercetin / curcumin No quercetin/curcumin CRS original was evaluated here. Cell or animal pathways cannot establish human treatment benefit. No primary CRS trial assessed here Financial provenance not assessed Insufficient

What chronic rhinosinusitis is

In adults, CRS requires at least 12 weeks of compatible symptoms and objective evidence of sinonasal inflammation. Cardinal symptoms include nasal blockage, discharge, facial pressure/pain and reduced smell. The clinician should establish whether nasal polyps are present; acute illness and allergic rhinitis require different assessment (2025 diagnostic guidance; Phenotype background).

Prevalence estimates depend on definitions and populations. Alharthi’s review reports approximately 10% from symptoms or findings alone and under 5% when both are required; these are cited background estimates, not a new global census. Stevens discusses nasal-polyps epidemiology, not a single rate applicable to every clinic or country (Review background; 2016 narrative).

How it works

The Stevens narrative proposes several contributors to nasal-polyp CRS: epithelial-barrier dysfunction, microbial exposures and dysregulated immune responses. Their roles are incompletely understood; this background does not establish one proven causal pathway or supplement treatment effect for all CRS (Original narrative).

Type-2/eosinophilic inflammation is common in some nasal-polyp populations, but inflammatory patterns vary geographically and between patients. Asthma often coexists. These mechanisms motivate targeted therapies; treatment effects require clinical evidence matched to the patient group (Mechanistic and clinical background; Adult clinical guidance).

Conventional treatment

The 2025 adult guideline recommends saline irrigation, topical nasal corticosteroids, or both, for symptomatic relief of CRS. Mawkili’s review combines six heterogeneous studies, mainly biologic add-ons, one enhanced-delivery comparison and a pediatric trial. Its participant summaries and quality-tool descriptions are inconsistent, and its −2.06 polyp-score figure belongs to a dupilumab study rather than a pooled steroid effect (Current adult recommendation; Original review).

Comparative evidence and financial limits Wu’s older abstract reports a three-drug indirect ranking; complete methods and funding/COI remain unavailable. The newer EVEREST trial directly compared two drugs in severe nasal-polyp CRS plus asthma and favored dupilumab on primary polyp/smell endpoints. Sanofi/Regeneron funded and participated throughout, with employee/stock and other commercial author disclosures. These different sources do not establish an independent all-drug winner or a universally safest biologic (Historical abstract; EVEREST original).

Current adult guidance discourages routine biologics for CRS without polyps. For polyp disease, it recommends discussion when medical and surgical care have failed or surgery is not viable, including patient preference. EVEREST provides a direct dupilumab–omalizumab comparison in severe polyp disease with asthma; Wu’s older abstract remains an indirect three-agent comparison. The U.S. tezepelumab label also covers inadequately controlled CRSwNP from age 12; local eligibility and product instructions govern prescribing (Adult guideline; EVEREST; Historical abstract; FDA label).

Antibiotics should not be routinely prescribed for adult CRS without an acute exacerbation or solely as a prerequisite for imaging or surgery. A suspected exacerbation requires clinical assessment; it does not automatically justify an antibiotic course. Persistent disease may warrant specialist surgical evaluation, and prescribed care remains individualized (2025 antibiotic guidance; Historical surgical context).

Supplement and lifestyle evidence

Intervention Evidence type (human) Effect size / finding Dose / duration Funding / conflict Grade
Saline irrigation Two unblinded trials; Original review; Summary Possible large-volume benefit, with low/very-low certainty and mixed diagnostic population. Current guidance recommends saline, INCS, or both. Study protocols differ; follow clinician/device instructions. NIHR award 14/174/03 and Cochrane ENT infrastructure support; several review authors disclosed device/pharmaceutical relationships. Rabago reported a Wisconsin departmental small grant; Cassandro acknowledged IBSA-sponsored editorial assistance. Trial conflict declarations and complete financing/supply terms remain incomplete. Weak trial set; guideline-supported
Xylitol irrigation 2011 postoperative pilot; 2024 postoperative trial Small below-threshold pilot signal; no significant superiority in the 70-person later trial. Pilot: ten days/arm; later trial: eight weeks starting one month after surgery. The 2024 mixing-unit errors preclude copying that paper as a home recipe. 2011: internal Stanford departmental support, no other funding/financial ties/COI disclosed. 2024: Taichung Veterans General Hospital grants TCVGH-1097326D/1107308D, no COI declared; underlying donors and purchase/donation terms not reported. Weak
Vitamin D Mixed-study review; 2023 postoperative original Selected low-vitamin-D postoperative population; associations do not prove causality. Trial attrition and duration wording limit interpretation. No routine all-CRS dose established; deficiency treatment requires clinical assessment. Review authors declared no competing interests; dedicated review cash support was not located. Ghazavi declared nil financial support and no conflicts; product procurement was not reported. Weak
Probiotics Four-trial original review No significant pooled SNOT effect; individual relapse signals and inconsistent route/follow-up reporting. No optimal preparation or regimen established. Review authors declared no competing interests and acknowledged hospital statistical advice. Dedicated cash support and included-trial financing/procurement were not reported in the recovered review. Weak; routine use unestablished
Bromelain Tissue-detection study; Registered results; Original synopsis No clinical efficacy from tissue detection. Registered primary symptom/rescue-medication and SNOT outcomes were not significant. Tissue study: 500 mg twice daily/30 days; placebo trial: 3,000 FIP/day/84 days. Research protocols, not recommended CRS doses. Tissue-study declarations/supply unclear; placebo trial Ursapharm-sponsored. Insufficient
Topical NAC 2024 postoperative trial No between-group SNOT-20, NOSE or endoscopic benefit; brief selected-symptom signals only. Thirty-day irrigation protocol; abstract and Methods disagree on frequency. Does not establish an oral NAC dose or home-mixing regimen. Chungbuk National University 2022 grant 2022101232; authors declared no COI and no funder role. Product purchase/donation terms were not reported. Weak; routine use unestablished
Essential oils No CRS original evaluated here. No chronic-disease benefit established by the evidence assessed here. No regimen established here. Not assessed Insufficient
Quercetin / curcumin No CRS original evaluated here. Mechanistic findings cannot establish human efficacy. No regimen established here. Not assessed Insufficient

Guideline-supported adult care and experimental adjuncts answer different questions. Saline/INCS recommendations do not require calling the two older saline trials high certainty. EVEREST supports a specific two-drug comparison in severe polyps plus asthma, not an all-biologic winner. Vitamin D, xylitol, probiotic and topical NAC studies have important population, reporting or endpoint limits; bromelain’s registered placebo trial did not demonstrate clinical benefit. None establishes a replacement for prescribed care (Adult guideline; Saline review; EVEREST; Vitamin D; Xylitol; Probiotic review; NAC; Bromelain).

Clinical guidance and adjunct evidence

Claim Verdict Notes
Saline irrigation Guideline-supported symptomatic care The two older saline trials provide low/very-low-certainty findings and do not determine an optimal volume or formulation (Adult guideline; Original review; Summary).
Topical nasal corticosteroids Guideline-supported option Recommended in adult CRS, alone or alongside saline. The heterogeneous 2025 review is not six isolated steroid-monotherapy trials (Adult recommendation; Original review; Historical background).
Dupilumab versus other biologics Specific direct and indirect evidence EVEREST favored dupilumab over omalizumab for primary polyp/smell outcomes in severe CRSwNP plus asthma; it did not compare all drugs. Wu’s historical ranking is indirect and its complete methods/disclosures remain unavailable (EVEREST; Historical abstract).
Xylitol nasal irrigation Mixed, preliminary evidence 2011 pilot signal was small; later 70-person postoperative RCT did not show superiority over saline (2011 xylitol pilot; 2024 xylitol trial)
Vitamin D Limited postoperative adjunct evidence Low-vitamin-D CRSwNP trial findings do not establish routine all-CRS supplementation; attrition and duration inconsistencies matter (Review; Original trial).
Probiotics Routine use unestablished No significant pooled SNOT effect. Relapse signals concern selected preparations/studies, and reporting does not establish an optimal product or route (Original review).
Bromelain Routine efficacy unestablished Tissue immunoreactivity is not symptom relief; the sponsored placebo trial’s primary symptom/rescue-medication and SNOT outcomes were not significant (Tissue study; Registry; Original synopsis).
Topical NAC Preliminary, limited postoperative evidence No overall symptom-questionnaire or endoscopic advantage; brief selected-symptom signals do not establish routine efficacy (Original trial).
Essential oils Not established here No CRS original evaluated here; no exhaustive absence claim.
Quercetin / curcumin Not established here No CRS original evaluated here. Cell/animal signals do not establish clinical benefit.

Risks and side effects

Effect / concern Frequency / certainty Evidence Notes
Saline irrigation Local effects reported; comparative safety uncertain Original Cochrane review; Summary; CDC water guidance The large-volume trial collected adverse effects only in the saline arm, preventing a between-group safety estimate. Use distilled, sterile, or boiled/cooled water; follow device instructions.
Xylitol irritation / tolerability Short-term, small-study findings 2011 pilot; 2024 trial Pilot: transient stinging and dislike of taste/gagging reported. Later trial reported no adverse events over eight weeks. Neither establishes complete long-term safety.
Bromelain with medicines A precaution; no quantified CRS interaction estimate NCCIH guidance; Tissue-study scope The tissue study did not test bleeding outcomes or medicine interactions. NCCIH advises reviewing any medicine use before bromelain; this article does not quantify anticoagulant/antiplatelet combination risk.
Bromelain allergy / stomach symptoms Stomach upset and diarrhea reported; allergy possible NCCIH bromelain; NCCIH allergy overview Known pineapple/bromelain allergy warrants avoidance and professional advice. These overviews do not quantify incidence in CRS patients.
Topical nasal corticosteroids Local irritation and nosebleeds can occur Guideline benefit/harm profile; Heterogeneous review Use the actual product label and prescriber instructions. This review does not quantify all long-term/high-dose class risks or every age group.
Biologic safety No universal safest drug established EVEREST; Historical abstract; Tezepelumab label EVEREST described similar overall adverse-event frequency in its selected population; rare/long-term comparative risks remain uncertain. Tezepelumab has product-specific hypersensitivity, helminth and live-vaccine precautions.

Selected medicine and product precautions

Substance / condition Evidence actually available Practical limit Source
Bromelain + anticoagulants The cited tissue study does not test this combination. Review the exact medicines and product with a clinician/pharmacist; no CRS-specific risk estimate established here. NCCIH medicine precaution; Tissue-study scope
Bromelain + antiplatelets No original combination-outcome study evaluated here. Review medicine/product use before supplementing; a proposed mechanism is not a measured bleeding rate. NCCIH medicine precaution
Bromelain + antibiotics This article does not supply verified human CRS interaction evidence Uncertain; clinician review advised NCCIH advises checking medicines before bromelain use (NCCIH bromelain guidance)
Saline irrigation These trials were not comprehensive drug-interaction studies. No assurance that every product/device/medicine combination is safe follows. Original review; Public summary
Xylitol irrigation Small efficacy/tolerability trials, not systematic medicine-interaction studies. No absence-of-interactions or long-term safety guarantee. 2011 pilot; 2024 trial
Specialist-prescribed biologics Precautions depend on the exact drug. For tezepelumab, no formal drug-interaction studies were performed; live attenuated vaccines should be avoided. Follow the actual local label and prescribing team; this label cannot be assigned unchanged to other biologics. Product-specific FDA label; Adult clinical guidance
Selected medicine precautions These CRS efficacy studies do not systematically quantify every medicine–supplement combination. Tissue detection and a no-conflict declaration are not interaction or safety proofs. NCCIH advises medicine review before bromelain; for prescribed biologics, use the actual product label and treating team’s assessment (Bromelain guidance; Tissue-study scope; Product-specific label).

Safety and clinical assessment

  • Use distilled or sterile water, or tap water that has been boiled and cooled, for nasal rinsing. Untreated tap water can carry organisms that cause rare serious infections (CDC water guidance).
  • Discuss bromelain with a clinician or pharmacist before use with any medicine, including anticoagulants and antiplatelets. The cited CRS tissue study does not measure combination bleeding risk; its proposed enzyme activity is not a validated interaction rate (NCCIH medicine precaution; Tissue-study scope).
  • Avoid bromelain with known pineapple or bromelain allergy; allergic reactions are possible (NCCIH). (NCCIH safety guidance)
  • The experimental adjuncts reviewed here should not replace diagnosed CRS care. Probiotic and topical NAC findings remain limited and preparation-specific; no quercetin/curcumin CRS original was evaluated. Treatment decisions should follow the diagnosed phenotype and clinical assessment (Adult guidance; Probiotic review; NAC original).
  • Persistent compatible symptoms need clinical assessment and objective confirmation of inflammation, including assessment for polyps and modifying conditions. Do not assume chronic infection or rely on supplements alone; an ENT referral may be appropriate according to findings and treatment response (2025 diagnostic guidance).

Research protocols and clinical instructions

Use case Protocol / instructions Duration / population Limits
Saline irrigation Follow clinician and device instructions. Adult guidance supports symptomatic use; older studies used different daily protocols. The older review does not establish an optimal volume, tonicity or duration. Use distilled, sterile, or boiled/cooled water (Adult guidance; Original review; Summary; CDC).
Xylitol irrigation Papers describe 5% research solutions; the 2024 paper contains erroneous milligram mixing units. Ten days/arm in the pilot; eight weeks starting one month after surgery in the later trial. Benefit over saline remains uncertain. These are research protocols, not a home-mixing recommendation. 2011 original; 2024 original
Bromelain tissue study 500 mg twice daily by mouth. Thirty days before tissue sampling. Immunoreactivity does not establish enzyme activity or symptom benefit. Separate placebo trial: 3,000 FIP/day for 84 days, without demonstrated clinical efficacy. Tissue original; Registered results; Original synopsis
Topical nasal corticosteroids Actual product label and prescriber instructions. Duration and delivery depend on the clinical plan. Adult guideline recommendation is separate from Mawkili’s mixed studies and historical narrative. Current guidance; 2025 review; 2016 background
Biologics Actual local prescribing information; no dose is selected from a network rank. Eligibility and duration require specialist assessment. EVEREST was a 24-week two-agent study in severe polyps plus asthma. Tezepelumab’s label is a separate product-specific authority. EVEREST; Historical abstract; FDA label
Topical NAC researchThirty-day postoperative irrigation protocol; abstract and Methods disagree on frequency.Adults with CRS without polyps after surgery, with shared antibiotics and fluticasone.No validated oral dose or home-mixing regimen follows. Full original trial

Mechanisms and limits of clinical inference

Cell/animal mechanisms cannot establish human CRS treatment effects. No quercetin or curcumin CRS original was evaluated in this article, so their grade reflects that evidence boundary rather than a certified absence of every human study. Mechanistic plausibility and a source’s academic affiliation also do not prove clinical efficacy, safety or financial independence.

The 2018 tissue study detected bromelain immunoreactivity after dosing, without testing symptom relief. A separate Ursapharm-sponsored 40-person placebo trial did not demonstrate benefit on its primary symptom/rescue-medication score or SNOT-20; peak nasal inspiratory flow favored placebo. These are different study questions; tissue detection should not be substituted for symptom or interaction outcomes (Original tissue study; Registered results; Original synopsis).

Reported funding and access limits

Follow the money

Research funding at a glance

Funding & backersSource & studyClaim & limits

13 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.

No single explicit tier could be mapped. This graphic does not assign a new tier or infer independence.

Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

The recovered original saline review reports NIHR support, commercial author relationships and substantial trial limitations. Rabago’s study reported a university departmental grant; Cassandro acknowledged IBSA-sponsored editorial assistance. Complete trial conflicts and supply/payment terms remain unresolved. A nonprofit label or guideline recommendation does not clear those financial questions (Full original declarations / trial tables; Public summary).

Mawkili authors declared no financial support for the submitted review and no relevant relationships; that does not clear every included drug trial’s financing. Wu’s full original methods and financial declarations remain unavailable despite publisher retrieval attempts. The 2024 vitamin D review declared no competing interests but has internal study-classification inconsistencies. Review funding, individual trial sponsorship and commercial author relationships must be distinguished (Original disclosures; Accessible original abstract; Original review).

Source Reported support / relationships Access actually obtained Remaining financial or evidential limits
Chong 2016 original; Summary NIHR award 14/174/03 and Cochrane ENT infrastructure support; several review authors disclosed device/pharmaceutical relationships. Rabago reported a Wisconsin departmental small grant; Cassandro acknowledged IBSA-sponsored editorial assistance. Trial conflict declarations and complete financing/supply terms remain incomplete. Full relevant Methods, results, trial tables and declarations read. Not all original constituent papers, cash amounts or product supply/payment terms verified.
Mawkili 2025 Authors declared no financial support for submitted work and no relevant financial/other relationships. Full relevant review Methods, results, Tables 1–2 and disclosures read. Heterogeneous add-ons/delivery/pediatric studies, inconsistent totals/tool descriptions; included-trial financing not cleared.
Wu historical NMA Complete original financial declarations unavailable. Complete primary abstract and publisher bibliographic record read; full paper access failed. Nine RCTs/1,190 participants, search through December 2020; no certification of full analysis, safety or financing.
Weissman 2011 Internal departmental funding; authors disclosed no other funding, financial ties or COI. Full relevant original pilot Methods/results/discussion/front disclosures read. Ultimate departmental donors and product purchase/donation terms unknown; sweet taste threatened blinding and attrition was substantial.
Alharthi / Alzarei 2024 No competing interests declared; dedicated review cash support not located. Full relevant review Methods, Tables 1–4, discussion and declaration read. Trial numbers/classifications conflict within the paper; included-study finances and causality remain unresolved.
Passali 2018; Bromelain registry; Trial synopsis Tissue paper: funding/COI/procurement not reported. Placebo trial: Ursapharm Arzneimittel GmbH sponsor. Full tissue Methods/results read; complete public eight-page sponsor synopsis read, not the 186-page report. Tissue detection is not efficacy; synopsis supplies null clinical outcomes but not complete payment/author-financial chains.
AAO-HNSF 2025 adult guidelineAAO-HNSF covered guideline costs. Authors disclosed pharmaceutical/device relationships and one supplement-business ownership; conflicts were managed by stated disclosure/recusal procedures.Scope, Methods, recommendation profiles/supporting sections and full financial disclosures read.Not all underlying studies or ultimate society donors traced.
De Corso 2025 EVERESTSanofi and Regeneron funded and participated in design, analysis, interpretation, writing and submission approval. Employee authors may hold stock/options; other commercial relationships and sponsor-funded medical writing were disclosed.Full relevant main Methods/results/Tables 1–3/limitations and complete disclosures read.Appendices, exact payments and drug procurement contracts not verified; selected two-agent population, 24 weeks.
Jiang 2024Taichung Veterans General Hospital grants TCVGH-1097326D/1107308D, no COI declared; underlying donors and purchase/donation terms not reported.Full relevant Methods/results/Tables 1–6/discussion/funding/COI read.Erroneous mass units and malformed p-value cells; no universal preparation or long-term safety conclusion.
Ghazavi 2023declared nil financial support and no conflicts; product procurement was not reported.Full relevant original Methods/results/Tables 1–3/discussion/finance read.Ten randomized participants excluded; duration and tabulated denominators are inconsistent.
Fong 2023Review authors declared no competing interests and acknowledged hospital statistical advice. Dedicated cash support and included-trial financing/procurement were not reported in the recovered review.Full relevant 12-page original Methods/results/tables/limitations and disclosures read.Route/timepoint descriptions conflict; original included-trial finances/procurement not cleared.
Wee 2024 NACChungbuk National University 2022 grant 2022101232; authors declared no COI and no funder role. Product purchase/donation terms were not reported.Full relevant Methods/results/Tables 1–2/discussion/finance read.Abstract/Methods frequency conflict, unblinded patients, multiple outcomes; no oral regimen or routine-use claim.
Stevens 2016 narrativeNLM lists NIAID NIH U19 AI106683 support. Dedicated full-paper funding/COI declarations were not located in the recovered manuscript.Original definition/phenotype/treatment/background sections and Primary grant record read.Historical narrative, not current prescribing authority or full author-financial clearance.

Frequently asked questions

What evidence supports saline irrigation?

Saline is a guideline-supported option for adult CRS symptom relief, alongside or instead of topical nasal corticosteroids according to the clinical plan. The older two-trial review has low/very-low-certainty findings and does not determine the best volume, tonicity or duration. Use safe water and follow device instructions (Adult guidance; Original review; Summary; CDC).

Where do nasal corticosteroids fit?

The adult guideline recommends saline, topical nasal corticosteroids, or both. Which formulation and delivery method suit a person depends on diagnosis, polyps, symptoms and treatment response. Mawkili’s mixed review cannot supply a universal steroid dose or six isolated monotherapy effects (Current guidance; Review scope; Historical background).

What does comparative biologic evidence show?

The 2022 abstract describes an indirect three-agent ranking and is no longer the only comparative evidence. In Sanofi/Regeneron-funded EVEREST, dupilumab beat omalizumab on primary polyp/smell endpoints after 24 weeks in adults with severe polyps and asthma. This does not rank all biologics or every phenotype. Tezepelumab’s U.S. label provides a separate current option for inadequately controlled CRSwNP from age 12; local assessment remains essential (Historical abstract; EVEREST original; FDA label; Adult guidance).

Does bromelain treat chronic rhinosinusitis?

The 2018 tissue study detected bromelain immunoreactivity after dosing, without testing symptom relief. A separate Ursapharm-sponsored 40-person placebo trial did not demonstrate benefit on its primary symptom/rescue-medication score or SNOT-20; peak nasal inspiratory flow favored placebo. The trial was small and its public synopsis is not the full report; routine efficacy is unestablished, rather than every possible benefit being disproved (Tissue original; Registered results; Synopsis).

Does vitamin D treat chronic rhinosinusitis?

Small postoperative studies in low-vitamin-D nasal-polyp populations report selected benefits. Ghazavi’s trial analyzed 60 of 70 randomized participants, with shared saline/fluticasone care and inconsistent treatment-duration descriptions. These findings do not establish routine supplementation for every CRS patient. Deficiency assessment and treatment need individualized clinical advice (Review; Original trial).

Does xylitol nasal rinse work?

The 2011 postoperative pilot analyzed 15 of 20 participants, with a small SNOT-20 difference below its stated clinical-importance threshold and no VAS benefit. The 2024 postoperative trial randomized 70 people one month after surgery and found no significant between-group superiority over saline after eight weeks. The 2024 paper contains mixing-unit errors, and neither trial establishes a universal home-treatment recipe or complete long-term safety (2011 original; 2024 original).

What does the probiotic review establish?

The four-trial review combined heterogeneous preparations and outcomes. Pooled SNOT scores were not significantly improved; a relapse signal came from selected individual studies rather than a universal effect. Reported routes and follow-up descriptions are inconsistent, so it does not establish an optimal product or regimen. The review declared no competing interests, but dedicated cash support and included-trial procurement were not reported. These findings do not establish routine CRS treatment or a substitute for prescribed care (Full original review).

Sources

This article is informational and does not replace assessment by a qualified clinician. It reviews the source sections actually available, with inaccessible originals, reporting inconsistencies and unreported financial details kept explicit. Editorial grades are qualitative judgments, not a new formal GRADE analysis.

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

We store your topic, message, optional email, and this page so we can manage and reply to the request. Do not include diagnoses, medications, or other sensitive medical information. See our Privacy Policy.